Therapeutics based on stop codon readthrough

Annual Review of Genomics and Human Genetics

Volumn 15, Issue , 2014, Pages 371-394

  Keeling, Kim M ^a   Xue, Xiaojiao ^a   Gunn, Gwen ^a   Bedwell, David M ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

nonsense mutation; nonsense suppression therapy; premature termination codons; readthrough

Indexed keywords

AMINOGLYCOSIDE; ANTIBIOTIC AGENT; ATALUREN; NON AMINOGLYCOSIDE ANTIBIOTIC; TRANSFER RNA; TRANSLATION TERMINATION FACTOR; UNCLASSIFIED DRUG; STOP CODON;

GENE REPRESSION; GENE THERAPY; GENETIC DISORDER; GENETIC PROCEDURES; HUMAN; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; PREMATURE TERMINATION CODON; PSEUDOURIDYLATION; REVIEW; STOP CODON; DRUG EFFECTS; GENETIC DISEASES, INBORN; GENETICS; PATHOLOGY; PROTEIN SYNTHESIS; RNA TRANSLATION;

CODON, NONSENSE; GENETIC DISEASES, INBORN; HUMANS; NONSENSE MEDIATED MRNA DECAY; PEPTIDE CHAIN TERMINATION, TRANSLATIONAL; PROTEIN BIOSYNTHESIS;

EID: 84904269218     PISSN: 15278204     EISSN: 1545293X     Source Type: Book Series    
DOI: 10.1146/annurev-genom-091212-153527     Document Type: Review

References (153)

1. Ali BH, Al Za'abi M, Blunden G, Nemmar A. 2011. Experimental gentamicin nephrotoxicity and agents that modify it: a mini-review of recent research. Basic Clin. Pharmacol. Toxicol. 109:225-32
2. Alkalaeva EZ, Pisarev AV, Frolova LY, Kisselev LL, Pestova TV. 2006. In vitro reconstitution of eu-karyotic translation reveals cooperativity between release factors eRF1 and eRF3. Cell 125:1125-36
3. Allamand V, Bidou L, Arakawa M, Floquet C, Shiozuka M, et al. 2008. Drug-induced readthrough of premature stop codons leads to the stabilization of laminin tx2 chain mRNA in CMD myotubes. J. Gene Med. 10:217-24
4. Amrani N, Ganesan R, Kervestin S, Mangus DA, Ghosh S, Jacobson A. 2004. A faux 3-UTR promotes aberrant termination and triggers nonsense-mediated mRNA decay. Nature 432:112-18
5. Arakawa M, Nakayama Y, Hara T, Shiozuka M, Takeda S, et al. 2001. Negamycin can restore dystrophin in mdx skeletal muscle. Acta Myol. 20:154-58
6. Arakawa M, Shiozuka M, Nakayama Y, Hara T, Hamada M, et al. 2003. Negamycin restores dystrophin expression in skeletal and cardiac muscles ofmdx mice. J. Biochem. 134:751-58
7. Auld DS, Lovell S, Thorne N, Lea WA, Maloney DJ, et al. 2010. Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc. Natl. Acad. Sci. USA 107:4878-83
8. Auld DS, Thorne N, Maguire WF, Inglese J. 2009. Mechanism of PTC124 activity in cell-based luciferase assays of nonsense codon suppression. Proc. Natl. Acad. Sci. USA 106:3585-90
9. Bartolomeo R, Polishchuk EV, Volpi N, Polishchuk RS, Auricchio A. 2013. Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. J. Inherit. Metab. Dis. 36:363-71
10. Barton-Davis ER, Cordier L, Shoturma DI, Leland SE, Sweeney HL. 1999. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles ofmdx mice. J. Clin. Investig. 104:375-81
11. Bell J. 2005. Amlexanox for the treatment of recurrent aphthous ulcers. Clin. Drug Investig. 25:555-66
12. Bhuvanagiri M, Schlitter AM, Hentze MW, Kulozik AE. 2010. NMD: RNA biology meets human genetic medicine. Biochem. J. 430:365-77
13. Brendel C, Belakhov V, Werner H, Wegener E, Gartner J, et al. 2010. Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J. Mol. Med. 89:389-98
14. Brumm H, Muhlhaus J, Bolze F, Scherag S, Hinney A, et al. 2012. Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through. Obesity 20:1074-81
15. Buck NE, Wood LR, Hamilton NJ, Bennett MJ, Peters HL. 2012. Treatment of a methylmalonyl-CoA mutase stopcodon mutation. Biochem. Biophys. Res. Commun. 427:753-57
16. Bunge S, Clements PR, Byers S, Kleijer WJ, Brooks DA, Hopwood JJ. 1998. Genotype-phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies. Biochim. Biophys. Acta 1407:249-56
17. Buvoli M, Buvoli A, Leinwand LA. 2000. Suppression of nonsense mutations in cell culture and mice by multimerized suppressor tRNA genes. Mol. Cell. Biol. 20:3116-24
18. Campbell KC, Meech RP, Klemens JJ, Gerberi MT, Dyrstad SS, et al. 2007. Prevention of noise-and drug-induced hearing loss with D-methionine. Hear. Res. 226:92-103
19. Cassan M, Rousset JP. 2001. UAG readthrough in mammalian cells: effect of upstream and downstream stop codon contexts reveal different signals. BMC Mol. Biol. 2:3
20. Chamberlain J. 1997. Dystrophin levels required for genetic correction of Duchenne muscular dystrophy Basic Appl. Myol. 7:251-55
21. Chan WK, Huang L, Gudikote JP, Chang YF, Imam JS, et al. 2007. An alternative branch of the nonsense-mediated decay pathway. EMBOJ. 26:1820-30
22. Chang CW, Hui Y, Elchert B, Wang J, Li J, Rai R. 2002. Pyranmycins, a novel class of aminoglycosides with improved acid stability: the SAR of D-pyranoses on ring III of pyranmycin. Org. Lett. 4:4603-6
23. Chavatte L, Kervestin S, Favre A, Jean-Jean O. 2003. Stop codon selection in eukaryotic translation termination: comparison of the discriminating potential between human and ciliate eRF1s. EMBO J. 22:1644-53
24. Chen C-YA, Shyu A-B. 2011. Mechanisms of deadenylation-dependent decay. Wiley Interdiscip. Rev. RNA 2:167-83
25. Clancy JP, Bebok Z, Ruiz F, King C, Jones J, et al. 2001. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 163:1683-92
26. Clancy JP, Dupont L, Konstan MW, Billings J, Fustik S, et al. 2013. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 68:818-25
27. +] propagation. Mol. Cell. Biol. 22:3301-15
28. Davidson DJ, Rolfe M. 2001. Mouse models of cystic fibrosis. Trends Genet. 17:S29-37
29. Drake KM, Dunmore BJ, McNelly LN, Morrell NW, Aldred MA. 2013. Correction ofnonsense BMPR2 and SMAD9 mutations by ataluren in pulmonary arterial hypertension. Am. J. Respir. Cell Mol. Biol. 49:403-9
30. Dranchak PK, Di Pietro E, Snowden A, Oesch N, Braverman NE, et al. 2011. Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J. Cell. Biochem. 112:1250-58
31. Du L, Damoiseaux R, Nahas S, Gao K, Hu H, et al. 2009. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J. Exp. Med. 206:2285-97
32. Du L, Jung ME, Damoiseaux R, Completo G, Fike F, et al. 2013. A new series of novel small molecular weight compounds induce readthrough of all three types of nonsense mutations in the ATM gene. Mol. Ther. 21:1653-60
33. Du M, Jones JR, Lanier J, Keeling KM, Lindsey JR, et al. 2002. Aminoglycoside suppression of a premature stop mutation in a Cftr-/-mouse carrying a human CFTR-G542X transgene. J. Mol. Med. 80:595-604
34. Du M, Keeling KM, Fan L, Liu X, Bedwell DM. 2009. Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. J. Biol. Chem. 284:6885-92
35. Du M, Keeling KM, Fan L, Liu X, Kovacs T, et al. 2006. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J. Mol. Med. 84:573-82
36. Du M, Liu X, Welch EM, Hirawat S, Peltz SW, Bedwell DM. 2008. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc. Natl. Acad. Sci. USA 105:2064-69
37. Durand S, Cougot N, Mahuteau-Betzer F, Nguyen CH, Grierson DS, et al. 2007. Inhibition of nonsensemediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J. Cell Biol. 178:1145-60
38. Durand S, Lykke-Andersen J. 2013. Nonsense-mediated mRNA decay occurs during eIF4F-dependent translation in human cells. Nat. Struct. Mol. Biol. 20:702-9
39. Eckford PD, Li C, Ramjeesingh M, Bear CE. 2012. Cystic fibrosis transmembrane conductance regulator (CFTR) potentiator VX-770 (ivacaftor) opens the defective channel gate of mutant CFTR in a phosphorylation-dependent but ATP-independent manner. J. Biol. Chem. 287:36639-49
40. Fan-Minogue H, Du M, Pisarev AV, Kallmeyer AK, Salas-Marco J, et al. 2008. Distinct eRF3 requirements suggest alternate eRF1 conformations mediate peptide release during eukaryotic translation termination. Mol. Cell 30:599-609
41. Finkel RS. 2010. Read-through strategies for suppression of nonsense mutations in Duchenne/Becker muscular dystrophy: aminoglycosides and ataluren (PTC124). J. Child Neurol. 25:1158-64
42. Floquet C, Rousset JP, Bidou L. 2011. Readthrough of premature termination codons in the adenomatous polyposis coli gene restores its biological activity in human cancer cells. PLoS ONE 6:e24125
43. Frischmeyer-Guerrerio PA, Montgomery RA, Warren DS, Cooke SK, Lutz J, et al. 2011. Perturbation of thymocyte development in nonsense-mediated decay (NMD)-deficient mice. Proc. Natl. Acad. Sci. USA 108:10638-43
44. Gehring NH, Kunz JB, Neu-Yilik G, Breit S, Viegas MH, et al. 2005. Exon-junction complex components specify distinct routes of nonsense-mediated mRNA decay with differential cofactor requirements. Mol. Cell 20:65-75
45. Giege R, Sissler M, Florentz C. 1998. Universal rules and idiosyncratic features in tRNA identity. Nucleic Acids Res. 26:5017-35
46. Gilbert DN, Wood CA, Kohlhepp SJ, Kohnen PW, Houghton DC, et al. 1989. Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J. Infect. Dis. 159:945-53
47. Goldmann T, Overlack N, Möller F, Belakhov V, van Wyk M, et al. 2012. A comparative evaluation of NB30, NB54 and PTC124 in translational read-through efficacy for treatment of an USH1C nonsense mutation. EMBO Mol. Med. 4:1186-99
48. Goldmann T, Overlack N, Wolfrum U, Nagel-Wolfrum K. 2011. PTC124 mediated translational read-through of a nonsense mutation causing Usher type 1C. Hum. Gene Ther. 22:537-47
49. Goldmann T, Rebibo-Sabbah A, Overlack N, Nudelman I, Belakhov V, et al. 2010. Beneficial read-through of a USH1C nonsense mutation by designed aminoglycoside NB30 in the retina. Investig. Oph-thalmol. Vis. Sci. 51:6671-80
50. Gong Q, Stump MR, Zhou Z. 2011. Inhibition of nonsense-mediated mRNA decay by antisense mor-pholino oligonucleotides restores functional expression of hERG nonsense and frameshift mutations in long-QT syndrome. J. Mol. Cell. Cardiol. 50:223-29
51. Gonzalez S, Beghyn T, Jia J, Debreuck N, Berte G, et al. 2012. Rescue of nonsense mutations by amlexanox in human cells. Orphanet J. Rare Dis. 7:58
52. Guerin K, Gregory-Evans CY, Hodges MD, Moosajee M, Mackay DS, et al. 2008. Systemic aminogly-coside treatment in rodent models of retinitis pigmentosa. Exp. Eye Res. 87:197-207
53. Harmer SC, Mohal JS, Kemp D, Tinker A. 2012. Readthrough of long-QT syndrome type 1 nonsense mutations rescues function but alters the biophysical properties of the channel. Biochem. J. 443:635-42
54. Hirawat S, Welch EM, Elfring GL, Northcutt VJ, Paushkin S, et al. 2007. Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single-and multiple-dose administration to healthy male and female adult volunteers. J. Clin. Pharmacol. 47:430-44
55. Hoshino S. 2012. Mechanism of the initiation of mRNA decay: role of eRF3 family G proteins. Wiley Interdiscip. Rev. RNA 3:743-57
56. Howard M, Frizzell RA, Bedwell DM. 1996. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 2:467-69
57. Howard MT, Shirts BH, Petros LM, Flanigan KM, Gesteland RF, Atkins JF. 2000. Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol. 48:164-69
58. Huang C, Wu G, Yu YT. 2012. Inducing nonsense suppression by targeted pseudouridylation. Nat. Protoc. 7:789-800
59. Hulka GF, Prazma J, Brownlee RE, Pulver S, Pillsbury HC. 1993. Use of poly-L-aspartic acid to inhibit aminoglycoside cochlear ototoxicity. Am. J. Otol. 14:352-56
60. Huth ME, Ricci AJ, Cheng AG. 2011. Mechanisms of aminoglycoside ototoxicity and targets of hair cell protection. Int. J. Otolaryngol. 2011:1-19
61. Ibba M, Hong KW, Sherman JM, Sever S, Soll D. 1996. Interactions between tRNA identity nucleotides and their recognition sites in glutaminyl-tRNA synthetase determine the cognate amino acid affinity of the enzyme. Proc. Natl. Acad. Sci. USA 93:6953-58
62. Imataka H, Gradi A, Sonenberg N. 1998. A newly identified N-terminal amino acid sequence of human eIF4G binds poly(A)-binding protein and functions inpoly(A)-dependent translation. EMBO J. 17:7480-89
63. James PD, Raut S, Rivard GE, Poon MC, Warner M, et al. 2005. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 106:3043-48
64. Karijolich J, Yu YT. 2011. Converting nonsense codons into sense codons by targeted pseudouridylation. Nature 474:395-98
65. Keeling KM, Wang D, Dai Y, Murugesan S, Chenna B, et al. 2013. Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS ONE 8:e60478
66. Keiser NW, Engelhardt JF. 2011. New animal models of cystic fibrosis: What are they teaching us? Curr. Opin. Pulm. Med. 17:478-83
67. Kellermayer R, Szigeti R, Keeling KM, Bedekovics T, Bedwell DM. 2006. Aminoglycosides as potential pharmacogenetic agents in the treatment of Hailey-Hailey disease. J. Investig. Dermatol. 126:229-31
68. Kerem E. 2004. Pharmacologic therapy for stop mutations: How much CFTR activity is enough? Curr. Opin. Pulm. Med. 10:547-52
69. Kerem E, Hirawat S, Armoni S, Yaakov Y, Shoseyov D, et al. 2008. Effectiveness of PTC124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372:719-27
70. Khajavi M, Inoue K, Lupski JR. 2006. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur. J. Hum. Genet. 14:1074-81
71. Kiselev AV, Ostapenko OV, Rogozhkina EV, Kholod NS, Seit Nebi AS, et al. 2002. Suppression of nonsense mutations in the dystrophin gene by a suppressor tRNA gene. Mol. Biol. 36:43-47
72. Konstan M, Accurso F, De Boeck K, Kerem E, Rowe S, et al. 2012. Targeting class 1 mutations: update on ataluren as a promising treatment for nonsense mutation cystic fibrosis. Pediatr. Pulmonol. 47(S35):108-9
73. Kramer EB, Vallabhaneni H, Mayer LM, Farabaugh PJ. 2010. A comprehensive analysis of translational missense errors in the yeast Saccharomyces cerevisiae. RNA 16:1797-808
74. Laski FA, Ganguly S, Sharp PA, RajBhandary UL, Rubin GM. 1989. Construction, stable transformation, and function of an amber suppressor tRNA gene in Drosophila melanogaster. Proc. Natl. Acad. Sci. USA 86:6696-98
75. Laurent G, Carlier MB, Rollman B, Van Hoof F, Tulkens P. 1982. Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin. Biochem. Pharmacol. 31:3861-70
76. Lee HL, Dougherty JP. 2012. Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol. Ther. 136:227-66
77. Linde L, Boelz S, Nissim-Rafinia M, Oren YS, Wilschanski M, et al. 2007. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J. Clin. Investig. 117:683-92
78. Lynch SR, Puglisi JD. 2001. Structural origins of aminoglycoside specificity for prokaryotic ribosomes. J. Mol. Biol. 306:1037-58
79. Lynch SR, Puglisi JD. 2001. Structure of a eukaryotic decoding region A-site RNA. J. Mol. Biol. 306:1023-35
80. Makino H, Saijo T, Ashida Y, Kuriki H, Maki Y. 1987. Mechanism of action of an antiallergic agent, amlexanox (AA-673), in inhibiting histamine release from mast cells. Acceleration of cAMP generation and inhibition of phosphodiesterase. Int. Arch. Allergy Appl. Immunol. 82:66-71
81. Malik V, Rodino-Klapac LR, Viollet L, Wall C, King W, et al. 2010. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol. 67:771-80
82. Manuvakhova M, Keeling K, Bedwell DM. 2000. Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6:1044-55
83. Mattis VB, Ebert AD, Fosso MY, Chang CW, Lorson CL. 2009. Delivery of a read-through inducing compound, TC007, lessens the severity of a spinal muscular atrophy animal model. Hum. Mol. Genet. 18:3906-13
84. McCaughan KK, Brown CM, Dalphin ME, Berry MJ, Tate WP. 1995. Translational termination efficiency in mammals is influenced by the base following the stop codon. Proc. Natl. Acad. Sci. USA 92:5431-35
85. McElroy SP, Nomura T, Torrie LS, Warbrick E, Gartner U, et al. 2013. A lack of premature termination codon read-through efficacy of PTC124 (Ataluren) in a diverse array of reporter assays. PLoS Biol. 11:e1001593
86. McIlwain DR, Pan Q, Reilly PT, Elia AJ, McCracken S, et al. 2010. Smg1 is required for embryogenesis and regulates diverse genes via alternative splicing coupled to nonsense-mediated mRNA decay. Proc. Natl. Acad. Sci. USA 107:12186-91
87. Medghalchi SM, Frischmeyer PA, Mendell JT, Kelly AG, Lawler AM, Dietz HC. 2001. Rent1, a trans-effector of nonsense-mediated mRNA decay, is essential for mammalian embryonic viability. Hum. Mol. Genet. 10:99-105
88. Mendell JT, Sharifi NA, Meyers JL, Martinez-Murillo F, Dietz HC. 2004. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat. Genet. 36:1073-78
89. Metze S, Herzog VA, Ruepp MD, Muhlemann O. 2013. Comparison of EJC-enhanced and EJC-independent NMD in human cells reveals two partially redundant degradation pathways. RNA 19:1432-48
90. Mort M, Ivanov D, Cooper DN, Chuzhanova NA. 2008. A meta-analysis of nonsense mutations causing human genetic disease. Hum. Mutat. 29:1037-47
91. Neri M, Torelli S, Brown S, Ugo I, Sabatelli P, et al. 2007. Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul. Disord. 17:913-18
92. Nguyen LS, Kim HG, Rosenfeld JA, Shen Y, Gusella JF, et al. 2013. Contribution of copy number variants involving nonsense-mediated mRNA decay pathway genes to neuro-developmental disorders. Hum. Mol. Genet. 22:1816-25
93. Nudelman I, Glikin D, Smolkin B, Hainrichson M, Belakhov V, Baasov T. 2010. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg. Med. Chem. 18:3735-46
94. Nudelman I, Rebibo-Sabbah A, Cherniavsky M, Belakhov V, Hainrichson M, et al. 2009. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J. Med. Chem. 52:2836-45
95. Nudelman I, Rebibo-Sabbah A, Shallom-Shezifi D, Hainrichson M, Stahl I, et al. 2006. Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. Bioorg. Med. Chem. Lett. 16:6310-15
96. Oussoren E, Keulemans J, van Diggelen OP, Oemardien LF, Timmermans RG, et al. 2013. Residual α-L-iduronidase activity in fibroblasts of mild to severe mucopolysaccharidosis type I patients. Mol. Genet. Metab. 109:377-81
97. Palmer E, Wilhelm JM. 1978. Mistranslation in a eucaryotic organism. Cell 13:329-34
98. Palmer E, Wilhelm JM, Sherman F. 1979. Phenotypic suppression of nonsense mutants in yeast by aminoglycoside antibiotics. Nature 277:148-50
99. Panchal RG, Wang S, McDermott J, Link CJ Jr. 1999. Partial functional correction of xeroderma pigmentosum group A cells by suppressor tRNA. Hum. Gene Ther. 10:2209-19
100. Peltz SW, Morsy M, Welch EM, Jacobson A. 2013. Ataluren as an agent for therapeutic nonsense suppression. Annu. Rev. Med. 64:407-25
101. Peltz SW, Welch EM, Jacobson A, Trotta CR, Naryshkin N, et al. 2009. Nonsense suppression activity of PTC124 (ataluren). Proc. Natl. Acad. Sci. USA 106:E64
102. Pichavant C, Aartsma-Rus A, Clemens PR, Davies KE, Dickson G, et al. 2011. Current status of pharmaceutical and genetic therapeutic approaches to treat DMD. Mol. Ther. 19:830-40
103. Piotrowska E, Jakobkiewicz-Banecka J, Baranska S, Tylki-Szymanska A, Czartoryska B, et al. 2006. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur. J. Hum. Genet. 14:846-52
104. Politano L, Nigro G, Nigro V, Piluso G, Papparella S, et al. 2003. Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol. 22:15-21
105. Qian Y, Guan MX. 2009. Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation. Antimicrob. Agents Chemother. 53:4612-18
106. Ramsammy L, Josepovitz C, Lane B, Kaloyanides GJ. 1990. Polyaspartic acid inhibits gentamicin-induced perturbations of phospholipid metabolism. Am. J. Physiol. 258:C1141-49
107. Rebibo-Sabbah A, Nudelman I, Ahmed ZM, Baasov T, Ben-Yosef T. 2007. In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome. Hum. Genet. 122:373-81
108. Recht MI, Douthwaite S, Puglisi JD. 1999. Basis for prokaryotic specificity of action of aminoglycoside antibiotics. EMBO J. 18:3133-38
109. Reilly SM, Chiang SH, Decker SJ, Chang L, Uhm M, et al. 2013. An inhibitor of the protein kinases TBK1 and IKK-varepsilon improves obesity-related metabolic dysfunctions in mice. Nat. Med. 19:313-21
110. Reiter RJ, Tan DX, Korkmaz A, Fuentes-Broto L. 2011. Drug-mediated ototoxicity and tinnitus: alleviation with melatonin. J. Physiol. Pharmacol. 62:151-57
111. Rowe SM, Sloane P, Tang LP, Backer K, Mazur M, et al. 2011. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J. Mol. Med. 89:1149-61
112. Rowe SM, Verkman AS. 2013. Cystic fibrosis transmembrane regulator correctors and potentiators. Cold Spring Harb. Perspect. Med. 3:a009761
113. Rufener SC, Muhlemann O. 2013. eIF4E-bound mRNPs are substrates for nonsense-mediated mRNA decay in mammalian cells. Nat. Struct. Mol. Biol. 20:710-17
114. Salas-Marco J, Bedwell DM. 2004. GTP hydrolysis by eRF3 facilitates stop codon decoding during eukaryotic translation termination. Mol. Cell. Biol. 24:7769-78
115. Salas-Marco J, Bedwell DM. 2005. Discrimination between defects in elongation fidelity and termination efficiency provides mechanistic insights into translational readthrough. J. Mol. Biol. 348:801-15
116. Salas-Marco J, Fan-Minogue H, Kallmeyer AK, Klobutcher LA, Farabaugh PJ, Bedwell DM. 2006. Distinct paths to stop codon reassignment by the variant-code organisms Tetrahymena and Euplotes. Mol. Cell. Biol. 26:438-47
117. Sanchez-Alcudia R, Perez B, Ugarte M, Desviat LR. 2012. Feasibility of nonsense mutation readthrough as a novel therapeutical approach in propionic acidemia. Hum. Mutat. 33:973-80
118. Sangkuhl K, Schulz A, Rompler H, Yun J, Wess J, Schoneberg T. 2004. Aminoglycoside-mediated rescue of a disease-causing nonsense mutation in the V2 vasopressin receptor gene in vitro and in vivo. Hum. Mol. Genet. 13:893-903
119. Sarkar C, Zhang Z, Mukherjee AB. 2011. Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. Mol. Genet. Metab. 104:338-45
120. Scheunemann AE, Graham WD, Vendeix FA, Agris PF. 2010. Binding of aminoglycoside antibiotics to helix 69 of 23S rRNA. Nucleic Acids Res. 38:3094-105
121. Schiffelers R, Storm G, Bakker-Woudenberg I. 2001. Liposome-encapsulated aminoglycosides in preclinical and clinical studies. J. Antimicrob. Chemother. 48:333-44
122. Schroers A, Kley RA, Stachon A, Horvath R, Lochmüller H, et al. 2006. Gentamicin treatment in McArdle disease: failure to correct myophosphorylase deficiency. Neurology 66:285-86
123. Schweingruber C, Rufener SC, Zund D, Yamashita A, Muhlemann O. 2013. Nonsense-mediated mRNA decay: mechanisms of substrate mRNA recognition and degradation in mammalian cells. Biochim. Biophys. Acta 1829:612-23
124. Seoighe C, Gehring C. 2010. Heritability in the efficiency of nonsense-mediated mRNA decay in humans. PLoS ONE 5:e11657
125. Sermet-Gaudelus I, Boeck KD, Casimir GJ, Vermeulen F, Leal T, et al. 2010. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med. 182:1262-72
126. ;-OH group for the treatment of genetic diseases in biological samples. J. Pharm. Biomed. Anal. 75:33-40
127. Simon AJ, Lev A, Wolach B, Gavrieli R, Amariglio N, et al. 2010. The effect of gentamicin-induced readthrough on a novel premature termination codon of CD18 leukocyte adhesion deficiency patients. PLoS ONE 5:e13659
128. Sutcliffe JA. 2005. Improving on nature: antibiotics that target the ribosome. Curr. Opin. Microbiol. 8:534-42
129. Tan L, Narayan SB, Chen J, Meyers GD, Bennett MJ. 2011. PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J. Inherit. Metab. Dis. 34:443-47
130. Tarpey PS, Raymond FL, Nguyen LS, Rodriguez J, Hackett A, et al. 2007. Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation. Nat. Genet. 39:1127-33
131. Tate WP, Poole ES, Horsfield JA, Mannering SA, Brown CM, et al. 1995. Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon. Biochem. Cell Biol. 73:1095-103
132. Temple GF, Dozy AM, Roy KL, Kan YW. 1982. Construction of a functional human suppressor tRNA gene: an approach to gene therapy for β-thalassaemia. Nature 296:537-40
133. Tomita K, Ueda T, Watanabe K. 1999. The presence of pseudouridine in the anticodon alters the genetic code: a possible mechanism for assignment of the AAA lysine codon as asparagine in echinoderm mitochondria. Nucleic Acids Res. 27:1683-89
134. Usuki F, Yamashita A, Higuchi I, Ohnishi T, Shiraishi T, et al. 2004. Inhibition of nonsense-mediated mRNA decay rescues the phenotype in Ullrich's disease. Ann. Neurol. 55:740-44
135. Usuki F, Yamashita A, Kashima I, Higuchi I, Osame M, Ohno S. 2006. Specific inhibition of nonsensemediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibro-blasts. Mol. Ther. 14:351-60
136. Usuki F, Yamashita A, Shiraishi T, Shiga A, Onodera O, et al. 2013. Inhibition of SMG-8, a subunit of SMG-1 kinase, ameliorates nonsense-mediated mRNA decay-exacerbated mutant phenotypes without cytotoxicity. Proc. Natl. Acad. Sci. USA 110:15037-42
137. Viegas MH, Gehring NH, Breit S, Hentze MW, Kulozik AE. 2007. The abundanceof RNPS1, aprotein component of the exon junction complex, can determine the variability in efficiency of the nonsense mediated decay pathway. Nucleic Acids Res. 35:4542-51
138. Wang B, Yang Z, Brisson BK, Feng H, Zhang Z, et al. 2010. Membrane blebbing as an assessment of functional rescue of dysferlin-deficient human myotubes via nonsense suppression. J. Appl. Physiol. 109:901-5
139. Wang D, Belakhov V, Kandasamy J, Baasov T, Li SC, et al. 2012. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol. Genet. Metab. 105:116-25
140. Weischenfeldt J, Damgaard I, Bryder D, Theilgaard-Monch K, Thoren LA, et al. 2008. NMD is essential for hematopoietic stem and progenitor cells and for eliminating by-products of programmed DNA rearrangements. Genes Dev. 22:1381-96
141. Welch EM, Barton ER, Zhuo J, Tomizawa Y, Friesen WJ, et al. 2007. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447:87-91
142. Wells SE, Hillner PE, Vale RD, Sachs AB. 1998. Circularization of mRNA by eukaryotic translation initiation factors. Mol. Cell 2:135-40
143. Wilhelm JM, Jessop JJ, Pettitt SE. 1978. Aminoglycoside antibiotics and eukaryotic protein synthesis: stimulation of errors in the translation of natural messengers in extracts of cultured human cells. Biochemistry 17:1149-53
144. Wilschanski M, Miller LL, Shoseyov D, Blau H, Rivlin J, et al. 2011. Chronic ataluren (PTC124) treatment of nonsense mutation cystic fibrosis. Eur. Respir. J. 38:59-69
145. Wilschanski M, Yahav Y, Yaacov Y, Blau H, Bentur L, et al. 2003. Gentamicin-induced correction of CFTR function in patients with cystic fibrosis and CFTR stop mutations. N. Engl. J. Med. 349:1433-41
146. Wohlgemuth I, Pohl C, Mittelstaet J, Konevega AL, Rodnina MV. 2011. Evolutionary optimization of speed and accuracy of decoding on the ribosome. Philos. Trans. R. Soc. Lond. B 366:2979-86
147. Yamashita A. 2013. Role of SMG-1-mediated Upf1 phosphorylation in mammalian nonsense-mediated mRNA decay. Genes Cells 18:161-75
148. Yang C, Feng J, Song W, Wang J, Tsai B, et al. 2007. A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin. Proc. Natl. Acad. Sci. USA 104:15394-99
149. Yang H, Wang H, Shivalila CS, Cheng AW, Shi L, Jaenisch R. 2013. One-step generation of mice carrying reporter and conditional alleles by CRISPR/Cas-mediated genome engineering. Cell 154:1370-79
150. Yukihara M, Ito K, Tanoue O, Goto K, Matsushita T, et al. 2011. Effective drug delivery system for Duchenne muscular dystrophy using hybrid liposomes including gentamicin along with reduced toxicity. Biol. Pharm. Bull. 34:712-16
151. Zhou Y, Jiang Q, Takahagi S, Shao C, Uitto J. 2013. Premature termination codon read-through in the ABCC6 gene: potential treatment for pseudoxanthoma elasticum.J. Investig. Dermatol. 133:2672-77
152. Zilberberg A, Lahav L, Rosin-Arbesfeld R. 2010. Restoration of APC gene function in colorectal cancer cells by aminoglycoside-and macrolide-induced read-through of premature termination codons. Gut 59:496-507
153. Zund D, Gruber AR, Zavolan M, Muhlemann O. 2013. Translation-dependent displacement of UPF1 from coding sequences causes its enrichment in 3 UTRs. Nat. Struct. Mol. Biol. 20:936-43